Clinical Trials Logo

Refractory Colorectal Cancer clinical trials

View clinical trials related to Refractory Colorectal Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06202417 Completed - Colorectal Cancer Clinical Trials

Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

Start date: January 1, 2021
Phase:
Study type: Observational

Fruquintinib is an oral tyrosine kinase inhibitor (TKI), which improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we explore the real-world treatment patterns of fruquintinib in the third- or late-line setting for mCRC in six centers in China.